var data={"title":"Cisplatin nephrotoxicity","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cisplatin nephrotoxicity</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Didier Portilla, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">A Mazin Safar, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Melissa L Shannon, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 14, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> is a potent and valuable chemotherapy agent used to treat a broad spectrum of malignancies. Renal tubular dysfunction and a cumulative impairment in renal function, as manifested by a decline in the glomerular filtration rate (GFR), can be dose limiting. The laboratory observation that forced hydration and diuresis may prevent nephrotoxicity facilitated the subsequent clinical development of cisplatin [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p>Cisplatin-induced renal toxicity is reviewed here. The use of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> in patients with pre-existing renal dysfunction and the renal effects of the platinum analogs, <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> and <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a>, are discussed elsewhere. (See <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple mechanisms contribute to renal dysfunction following exposure to <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>. These include tubular epithelial cell toxicity, vasoconstriction in the renal microvasculature, and proinflammatory effects [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Cellular toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> is a potent cellular toxin, particularly in a low-chloride environment. In the interior of cells, chloride atoms in cisplatin are replaced by water molecules. This hydrolysis product is believed to be the active species, reacting with glutathione in the cytoplasm and DNA in the nucleus [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/5\" class=\"abstract_t\">5</a>]. In tumors and other dividing cells, cisplatin-DNA intrastrand crosslinks result in cytotoxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/6\" class=\"abstract_t\">6</a>]. These molecular events are thought to be responsible for arresting cancer cell proliferation. More than 50 percent of the drug is excreted in the urine in the first 24 hours following cisplatin administration, and the concentration of platinum achieved in the renal cortex is several-fold greater than that in plasma and other organs [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Cisplatin primarily injures the S3 segment of the proximal tubule, causing a decrease in the glomerular filtration rate (GFR) [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Experimental studies suggest that basolateral drug transporters play a role in <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> uptake [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/10\" class=\"abstract_t\">10</a>]. Changes in expression of proximal tubule organic cation transporter-2 (OCT2) have been shown to mediate the accumulation of cisplatin in proximal tubular epithelial cells, which suggests a key role for OCT2 in the development of cisplatin-mediated nephrotoxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/11-13\" class=\"abstract_t\">11-13</a>]. The organic anion transporters OAT1 and OAT3 may also play a role via a mechanism that is independent of OCT2 [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Vasoconstriction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vasoconstriction in the renal microvasculature appears to contribute to decreased renal blood flow soon after <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> injection [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/15,16\" class=\"abstract_t\">15,16</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Proinflammatory effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> increases the expression of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), interferon-gamma (IFN-gamma), and caspases, which promote the differentiation, maturation, and activation of neutrophils, T cells, and other components of the cellular inflammatory response [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Experimental models of cisplatin-induced acute kidney injury (AKI) demonstrate increased expression of endothelial cell adhesion molecules and subsequent infiltration of leukocytes and T cells in kidney tissue [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/19-21\" class=\"abstract_t\">19-21</a>]. The potential importance of these mediators was illustrated by the lesser severity of AKI following exposure to cisplatin in mice with defects in these inflammatory pathways [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/17,18,22-24\" class=\"abstract_t\">17,18,22-24</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Effects on the proximal tubule</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The proximal tubule cells are selectively injured by <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, as manifested by both necrosis and apoptosis, even though nonproliferating cells are generally less sensitive to the toxicity of agents that damage DNA [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Possible reasons for the observed nephrotoxicity of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> include its enhanced renal uptake by organic transporters [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/10\" class=\"abstract_t\">10</a>]. This is followed by cisplatin-mediated reduced expression and function of sodium-dependent glucose and amino acid transporters [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/26\" class=\"abstract_t\">26</a>], reduced expression and function of magnesium and water transporters [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/7,8\" class=\"abstract_t\">7,8</a>], metabolism of cisplatin to glutathione and cysteinyl-glycine conjugates [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/27\" class=\"abstract_t\">27</a>], and the generation of reactive oxygen species [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/28-34\" class=\"abstract_t\">28-34</a>].</p><p>Other cellular effects that have been proposed as the cause of cisplatin-induced nephrotoxicity include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inhibition of mitochondrial F1F0-ATPase and reduction of mitochondrial oxidative phosphorylation precede apoptotic cell death [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/35,36\" class=\"abstract_t\">35,36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Induction of hyperlipidemia and the accumulation of triglyceride and nonesterified fatty acids (NEFAs) in kidney tissue, perhaps due to inhibition of fatty acid oxidation in the proximal tubule [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Significant reduction in mRNA levels and enzyme activity of mitochondrial medium chain acyl-CoA dehydrogenase (MCAD).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible direct inhibition of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activity in renal epithelial cells [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/38,39\" class=\"abstract_t\">38,39</a>]. This may decrease the expression of PPAR-regulated genes, including those encoding potentially protective fatty acid binding proteins [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/40\" class=\"abstract_t\">40</a>].</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most important manifestation of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nephrotoxicity is renal impairment, which can be progressive. Other renal manifestations have been described, including hypomagnesemia, salt wasting, a Fanconi-like syndrome, and anemia.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Renal impairment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of renal impairment varies, depending upon the dose and frequency of drug administration and the criteria used to define nephrotoxicity. Nephrotoxicity was observed in the initial phase-I and phase-II studies with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and was seen in more than 50 percent of cases in some of the early trials prior to the use of intensive hydration regimens [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/1,41\" class=\"abstract_t\">1,41</a>].</p><p>The incidence and severity of renal failure increases with subsequent courses and can eventually become irreversible. As a result, discontinuing therapy with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> is generally indicated in those who develop evidence of progressive renal impairment.</p><p>These observations apply to the administration of conventional doses of platinum. Despite its potent antitumor activity, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> cannot be used in the higher doses needed for bone marrow ablation prior to hematopoietic stem cell transplantation, because of severe toxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/42\" class=\"abstract_t\">42</a>]. <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">Carboplatin</a>, a less toxic analog, is often used in this setting.</p><p>Unless the renal failure is advanced, the urine output in patients with nephrotoxicity typically remains above 1000 mL per day due to the induction of a concentrating defect. This defect may reflect platinum-induced damage to the loop of Henle, where the countercurrent gradient required for urinary concentration is established, or to the collecting tubules, the site of action of antidiuretic hormone&nbsp;[<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/43\" class=\"abstract_t\">43</a>]. Injury to the collecting tubules is associated with decreased expression of aquaporin water channels [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/44\" class=\"abstract_t\">44</a>]. <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> nephrotoxicity also appears to be mediated by the organic cation transporter (hOCT2) [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Thrombotic microangiopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> may be associated with a different form of renal failure when given with <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, a thrombotic microangiopathy with features of the hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/46\" class=\"abstract_t\">46</a>]. A thrombotic microangiopathy has also been described when cisplatin is given with <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>. This disorder presumably reflects direct vascular injury with secondary platelet activation.</p><p>The onset of renal failure may be abrupt or insidious; in the latter setting, it can develop months after treatment has been discontinued. The diagnosis of this form of nephrotoxicity is suggested by the concurrent presence of a microangiopathic hemolytic anemia and thrombocytopenia. (See <a href=\"topic.htm?path=pathophysiology-of-acquired-ttp-and-other-primary-thrombotic-microangiopathies-tmas\" class=\"medical medical_review\">&quot;Pathophysiology of acquired TTP and other primary thrombotic microangiopathies (TMAs)&quot;</a> and <a href=\"topic.htm?path=acquired-ttp-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Acquired TTP: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Hypomagnesemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypomagnesemia due to urinary magnesium wasting occurs in over one-half of cases of cisplatin-induced nephrotoxicity and can be severe [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/47-49\" class=\"abstract_t\">47-49</a>]. In addition to its direct clinical manifestations, hypomagnesemia may exacerbate <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> toxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/50\" class=\"abstract_t\">50</a>].</p><p>Normal subjects are able to make the urine virtually magnesium-free once the plasma magnesium concentration falls below 1.2 <span class=\"nowrap\">mEq/L</span> (1.5 <span class=\"nowrap\">mg/dL</span> or 0.6 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/48\" class=\"abstract_t\">48</a>]. Thus, a fractional excretion of magnesium (FEMg) above 2.5 percent is indicative of some component of magnesium wasting in the presence of hypomagnesemia. A review of magnesium handling and of the different units used to measure the plasma magnesium concentration is available in a separate topic review. (See <a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">&quot;Regulation of magnesium balance&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Fanconi-like syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cisplatin-mediated nephrotoxicity is accompanied by the development of a Fanconi-like syndrome, with increased urinary excretion of glucose and amino acids (such as alanine, valine, leucine, methionine) and the presence of tricarboxylic acid (TCA) cycle metabolites (lactate and pyruvate) in the urine. In addition to being a marker of tubular damage, glucosuria may also occur due to cisplatin-induced glucose intolerance and hyperglycemia due to abnormal insulin and glucagon responses to a glucose stimulus [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/36,51-53\" class=\"abstract_t\">36,51-53</a>]. Classic Fanconi syndrome has not been reported, although mild tubular dysfunction may persist [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=overview-and-pathophysiology-of-renal-tubular-acidosis-and-the-effect-on-potassium-balance#H42786907\" class=\"medical medical_review\">&quot;Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance&quot;, section on 'Proximal (type 2) RTA'</a>.)</p><p>In addition, nonspecific urinary markers of glomerular (high-molecular-weight proteins) and tubular toxicity (such as N-acetyl-beta-glucosaminidase [NAG]) are significantly elevated in acute <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nephrotoxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/55\" class=\"abstract_t\">55</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Salt wasting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinically apparent renal salt wasting is a rare manifestation of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nephrotoxicity that has been described in case reports and small series [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/56,57\" class=\"abstract_t\">56,57</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> is frequently associated with anemia that is out of proportion to its myelosuppressive effect on the other blood cell lines. Animal and human studies suggest that the renal tubular injury induced by cisplatin results in a deficiency of erythropoietin, which contributes to the anemia [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/58\" class=\"abstract_t\">58</a>].</p><p>Treatment with erythropoiesis-stimulating agents may be useful in this situation. (See <a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">RISK FACTORS FOR ACUTE KIDNEY INJURY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An increasing risk of acute kidney injury (AKI) is associated with higher doses of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> that result in high peak plasma free platinum concentrations, previous exposure to cisplatin, pre-existing kidney damage, and the concomitant use of other nephrotoxic agents.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High peak plasma free platinum concentrations &ndash; High peak plasma free platinum concentrations are associated with an increased risk of AKI, which suggests that the cumulative dose of platinum may play a role in the development of nephrotoxicity. As an example, in a study of 22 patients receiving their first course of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> (50 to 140 <span class=\"nowrap\">mg/m<sup>2</sup>),</span> the peak plasma concentration of free platinum correlated with glomerular toxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/59\" class=\"abstract_t\">59</a>]. A peak plasma ultrafiltrable platinum level (free platinum level) in excess of 400 <span class=\"nowrap\">ng/mL</span> was associated with &gt;30 percent decline in creatinine clearance by the fourth course of therapy.</p><p/><p class=\"bulletIndent1\">Additional evidence supporting the importance of high peak plasma platinum concentrations comes from the observation that glomerular filtration rate (GFR) and serum magnesium levels were significantly decreased following <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> administration at doses &ge;50 <span class=\"nowrap\">mg/m<sup>2</sup></span> [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/60\" class=\"abstract_t\">60</a>]. By comparison, the GFR was maintained in patients receiving cisplatin at a lower daily dose of 20 <span class=\"nowrap\">mg/m<sup>2</sup></span> over five consecutive days [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/60\" class=\"abstract_t\">60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Previous <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> chemotherapy &ndash; Patients who are treated with salvage therapy after relapse following standard-dose, cisplatin-based, first-line treatment are at increased risk for developing renal failure with additional cisplatin therapy. An increased risk of nephrotoxicity may also be observed when <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a>, a less nephrotoxic platinum analog, is used instead of cisplatin in a salvage regimen [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/61\" class=\"abstract_t\">61</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pre-existing kidney damage &ndash; There is an increased risk of AKI with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> among patients with underlying kidney dysfunction, primarily due to the decreased renal clearance of cisplatin. Cisplatin-based chemotherapy is therefore considered contraindicated in patients with elevated serum creatinine levels.</p><p/><p class=\"bulletIndent1\">There are no definitive studies to help guide the threshold level of renal function at which <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> is not administered. In our centers, we make every effort to avoid using cisplatin among patients with a serum creatinine concentration &gt;1.5 <span class=\"nowrap\">mg/dL</span> (133 <span class=\"nowrap\">micromol/L)</span> or an estimated GFR (eGFR) of &lt;50 <span class=\"nowrap\">mL/min</span>. Possible exceptions are situations in which cisplatin has a proven curative role, such as patients with testicular cancer. Many of the ongoing national clinical trials exclude patients with creatinine levels &gt;1.5 <span class=\"nowrap\">mg/dL</span> (133 <span class=\"nowrap\">micromol/L)</span> from receiving cisplatin [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/62\" class=\"abstract_t\">62</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Concomitant administration of potentially nephrotoxic agents, such as aminoglycosides and amphotericin B.</p><p/><p>Other factors are potentially associated with an increased risk of renal toxicity. In a study of 400 patients treated with weekly high-dose <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> (70 to 85 <span class=\"nowrap\">mg/m<sup>2</sup>),</span> risk factors included older age, female gender, smoking, hypoalbuminemia, and <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> coadministration [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/63,64\" class=\"abstract_t\">63,64</a>]. The risk related to gender may be due in part to lower unbound cisplatin clearance in women.</p><p>Similar findings were reported in an observational study of two large cohorts of patients (4481 patients total) with all types of cancer that evaluated the risk of AKI after a first course of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/65\" class=\"abstract_t\">65</a>]. At baseline, mean eGFR in the two cohorts was 87.3 and 92.5 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>; patients with a serum creatinine &gt;1.5 <span class=\"nowrap\">mg/dL</span> (133 <span class=\"nowrap\">micromol/L)</span> were excluded. Cisplatin-induced AKI (defined as a 0.3 <span class=\"nowrap\">mg/dL</span> rise in serum creatinine within 14 days of receiving cisplatin) occurred in 13.6 and 11.6 percent of patients. Factors significantly associated with cisplatin-induced AKI included age &gt;60 years, cisplatin dose &gt;100 mg, history of hypertension, and serum albumin 2.0 to 3.5 <span class=\"nowrap\">g/dL;</span> baseline eGFR was not associated with an increased risk of AKI. A risk prediction model, which assigned patients scores for each of these risk factors, was developed to predict the risk of AKI using data from the first cohort and validated using data from the second cohort. Higher scores correlated with an increased incidence of AKI in both cohorts (4 and 8 percent for a score of 0 to 3, 14 and 15 percent for a score of 3.5 to 6, and 39 and 28 percent for scores &gt;6). The probability of cisplatin-induced AKI at scores of 3, 5.5, and 8.5 was 10, 24, and 51 percent, respectively. Additional studies will be required to determine the utility of this model in clinical practice.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The standard approach to prevent cisplatin-induced nephrotoxicity is the administration of lower doses of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, compared with previous regimens, in combination with intravenous isotonic saline. Although a number of pharmacologic agents have been evaluated to decrease nephrotoxicity, none has an established role.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Lower doses of cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As the spectrum of antitumor activity of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> has become better understood, newer chemotherapy regimens have been developed for palliative settings (eg, non-small cell lung cancer) that have facilitated the use of lower doses of cisplatin in conjunction with other, newer chemotherapy agents. This approach has minimized the incidence of nephrotoxicity without lowering the therapeutic efficacy of cisplatin. In contrast, the doses of cisplatin are not lowered in settings in which cure is the goal of therapy (eg, small cell lung and testicular germ cell tumors).</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Intravenous saline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is difficult to accurately characterize the effectiveness of intravenous saline in preventing <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nephrotoxicity. This is because, among the trials that have evaluated cisplatin, there were varying definitions of nephrotoxicity, variable cisplatin doses, and patient populations that differed by comorbidity and underlying malignancy.</p><p>In general, the administration of intravenous saline with the resultant diuresis significantly lowers the risk of nephrotoxicity. In the initial phase-I and II studies, nephrotoxicity was observed in more than 50 percent of cases administered <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/1,41\" class=\"abstract_t\">1,41</a>]. It was subsequently observed that the induction of a diuresis using the administration of intravenous saline dramatically lowered the incidence of nephrotoxicity to very low levels (0 percent in some small, uncontrolled series) [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/66\" class=\"abstract_t\">66</a>]. This allowed the development of cisplatin for clinical use [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The administration of intravenous saline to induce a diuresis remains the primary approach for preventing cisplatin-induced nephrotoxicity and must be used in all patients treated with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>. The optimal hydration solution and regimen to prevent nephrotoxicity associated with cisplatin administration is unclear. There are no randomized trials that have compared different regimens <span class=\"nowrap\">and/or</span> types of intravenous fluids. A systematic review of 24 studies that examined hydration strategies found that short-duration (over two to six hours), lower-volume (2 to 4 L) hydration with magnesium supplementation in the outpatient setting was effective and safe in preventing cisplatin-induced nephrotoxicity, even in those receiving intermediate- to high-dose cisplatin [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/67\" class=\"abstract_t\">67</a>]. However, given the differences in cancer types, cisplatin doses, study types, hydration regimens, and definitions of nephrotoxicity across studies, no definitive conclusions could be made regarding optimal hydration regimens.</p><p>We prepare a solution consisting of 1000 mL of isotonic saline plus 20 mEq of <a href=\"topic.htm?path=potassium-chloride-drug-information\" class=\"drug drug_general\">potassium chloride</a> and 2 grams of <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a>. We administer intravenously a minimum of 1000 mL of this solution over two to three hours prior to, and a minimum of 500 mL over the two hours following, the <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> administration. This fluid administration should be adequate to establish a urine flow of at least 100 <span class=\"nowrap\">mL/hour</span> for two hours prior to, and two hours after, chemotherapy administration. Among patients in whom this regimen is contraindicated, alternate chemotherapeutic regimens that do <strong>not</strong> include cisplatin should be considered.</p><p><a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">Mannitol</a> is frequently used to induce diuresis, although there is no evidence that this is required. It may be appropriate in select patients, such as those treated with high-dose <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> (&ge;100 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> <span class=\"nowrap\">and/or</span> those with preexisting hypertension [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/67\" class=\"abstract_t\">67</a>]. The addition of <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">furosemide</a> is generally not required, unless there is evidence of fluid overload.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Cisplatin analogs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The less nephrotoxic analog, <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a>, has been substituted for <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> in many chemotherapy regimens (eg, ovarian cancer, non-small cell lung cancer). The relative activity of cisplatin and carboplatin in different diseases needs to be considered in determining whether or not this is a feasible approach. (See <a href=\"topic.htm?path=first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ovarian-fallopian-tubal-and-peritoneal-cancer\" class=\"medical medical_review\">&quot;First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer&quot;</a> and <a href=\"topic.htm?path=systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation\" class=\"medical medical_review\">&quot;Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Amifostine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">Amifostine</a>, an organic thiophosphate, may protect against cisplatin-induced toxicity by donating a protective thiol group, an effect that is highly selective for normal, but not malignant, tissue [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/68\" class=\"abstract_t\">68</a>]. Treatment with amifostine prior to <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> administration decreased nephrotoxicity in animal models and preliminary clinical studies [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/69\" class=\"abstract_t\">69</a>].</p><p>A phase-III trial in women with ovarian cancer found that <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">amifostine</a> reduced the incidence of nephrotoxicity (&ge;40 percent reduction in creatinine clearance) from 33 to 10 percent with six cycles of a chemotherapy regimen that included <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> (100 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/62\" class=\"abstract_t\">62</a>].</p><p>On the basis of these results, the 2002 guidelines from the American Society of Clinical Oncology stated that <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">amifostine</a> could be considered in patients receiving repeated administrations of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> for ovarian or non-small cell lung cancer [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/70\" class=\"abstract_t\">70</a>], a position that was reiterated in the updated 2008 guidelines, with no new data on which to base a change in the recommendation [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/71\" class=\"abstract_t\">71</a>]. However, these studies used higher doses of cisplatin than are typical of contemporary regimens (which almost all use either a single bolus dose of 75 to 80 <span class=\"nowrap\">mg/m<sup>2</sup></span> or, in the setting of a germ cell tumor, a split dose of 20 <span class=\"nowrap\">mg/m<sup>2</sup></span> daily for five days), and there are no data supporting the use of amifostine in other settings. (See <a href=\"topic.htm?path=initial-risk-stratified-treatment-for-advanced-testicular-germ-cell-tumors\" class=\"medical medical_review\">&quot;Initial risk-stratified treatment for advanced testicular germ cell tumors&quot;</a> and <a href=\"topic.htm?path=extensive-stage-small-cell-lung-cancer-initial-management\" class=\"medical medical_review\">&quot;Extensive stage small cell lung cancer: Initial management&quot;</a>.)</p><p>We do <strong>not</strong> use <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">amifostine</a> to prevent cisplatin-induced nephrotoxicity. The principal reasons include the availability of newer regimens that use lower doses of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> or substitute <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> for cisplatin and the significant toxicity (nausea, vomiting, hypotension) and costs associated with the administration of amifostine. Furthermore, concerns persist about possible interference with the antitumor efficacy of cisplatin. Amifostine should not be used in settings in which chemotherapy can produce a significant survival advantage or chance of cure.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Other chemopreventive agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several other approaches have been evaluated to prevent cisplatin-induced nephrotoxicity. None of the following agents have an established role in patients being treated with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Sodium thiosulfate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with intraperitoneal tumors may be treated with intraperitoneal <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> or <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> to achieve high local drug levels and relatively low plasma concentrations. In this setting, intravenous <a href=\"topic.htm?path=sodium-thiosulfate-drug-information\" class=\"drug drug_general\">sodium thiosulfate</a> was given concurrently to bind covalently with the platinum that enters the systemic circulation. The resulting complex has no systemic or renal toxicity and also has no antitumor effect [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/72,73\" class=\"abstract_t\">72,73</a>].</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h3\">N-acetylcysteine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other thiols, such as N-acetylcysteine (NAC), were evaluated for primary prophylaxis and may have some role in preventing platinum nephrotoxicity in high-risk patients. Thiols are thought to act both on the death receptor and the mitochondrial apoptotic pathways that are induced by <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/74\" class=\"abstract_t\">74</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h3\">Theophylline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of <a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">theophylline</a> was suggested by a study in rats in which <a href=\"topic.htm?path=aminophylline-drug-information\" class=\"drug drug_general\">aminophylline</a> prevented cisplatin-induced nephrotoxicity [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/75\" class=\"abstract_t\">75</a>]. In an exploratory clinical trial, 41 patients were randomly assigned to receive theophylline or placebo in conjunction with chemotherapy that included one dose of <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> (50 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/76\" class=\"abstract_t\">76</a>]. Patients treated with theophylline had no change in glomerular filtration rate (GFR), while a significant decrease was observed in those receiving placebo (92.9 versus 71.8 <span class=\"nowrap\">mL/min)</span>. Additional clinical studies will be required to confirm these observations, particularly when patients receive higher doses of cisplatin and multiple cycles of chemotherapy.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Glycine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cisplatin-induced nephrotoxicity has been minimized in experimental models by the administration of glycine, but not other amino acids [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/77\" class=\"abstract_t\">77</a>], and a peroxisome proliferator-activated alpha ligand [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/36\" class=\"abstract_t\">36</a>]. Complementary and alternative agents, such as milk thistle and the flavonoid antioxidant, quercetin, have shown some protective effects in laboratory models of cisplatin-induced nephrotoxicity. The clinical utility of these agents remains to be determined.</p><p class=\"headingAnchor\" id=\"H554610594\"><span class=\"h3\">Polymeric cisplatin nanoparticles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polymeric <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nanoparticles that target the endolysosomal compartment of cancer cells may limit nephrotoxicity, but their clinical utility has not been shown [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/78\" class=\"abstract_t\">78</a>].</p><p class=\"headingAnchor\" id=\"H435708950\"><span class=\"h3\">Cell cycle inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A study provides evidence that the cell cycle inhibitors, <a href=\"topic.htm?path=palbociclib-drug-information\" class=\"drug drug_general\">palbociclib</a> and <a href=\"topic.htm?path=ribociclib-drug-information\" class=\"drug drug_general\">ribociclib</a>, may prevent acute kidney injury (AKI) by inhibiting renal cell cycle progression and organic cation transporter 2 [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/79\" class=\"abstract_t\">79</a>]. The development of cyclin dependent kinase inhibitors may provide renoprotection.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">General approach to renal dysfunction or failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The general approaches to the management of acute renal dysfunction and renal failure are discussed separately. (See <a href=\"topic.htm?path=overview-of-the-management-of-acute-kidney-injury-in-adults\" class=\"medical medical_review\">&quot;Overview of the management of acute kidney injury in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h2\">Discontinuation of cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> should be discontinued in the presence of acute kidney injury (AKI), which is defined as an increase in the serum creatinine concentration of &ge;50 percent over baseline levels or a reduction in urine output &lt;0.5 <span class=\"nowrap\">mL/kg</span> per hour for greater than six hours. Timely discontinuation of cisplatin may prevent progressive renal failure.</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Hypomagnesemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of hypomagnesemia generally consists of magnesium supplementation. High doses may be required since raising the plasma magnesium concentration will increase the degree of urinary magnesium wasting. The treatment of hypomagnesemia is discussed elsewhere [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/80\" class=\"abstract_t\">80</a>]. (See <a href=\"topic.htm?path=evaluation-and-treatment-of-hypomagnesemia\" class=\"medical medical_review\">&quot;Evaluation and treatment of hypomagnesemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h2\">Thrombotic microangiopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The specific treatment of thrombotic microangiopathy resulting from <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and other chemotherapeutic agents is discussed separately. (See <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy#H10429277\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Long-term follow-up of patients exposed to <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> indicates that renal function either remains stable or improves over time in patients with a glomerular filtration rate (GFR) &gt;60 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup> at the end of therapy [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/81,82\" class=\"abstract_t\">81,82</a>]. Whether such improvement reflects an increase in the number of functioning nephrons or hypertrophy of nephrons that remained relatively intact is unclear [<a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/83,84\" class=\"abstract_t\">83,84</a>].</p><p class=\"headingAnchor\" id=\"H354165833\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acute-kidney-injury-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute kidney injury in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin</a> is a potent antitumor agent usually administered in combination with other chemotherapy agents to treat a broad spectrum of malignancies. Cisplatin-induced nephrotoxicity is a dose-limiting side effect, which most commonly is manifested by acute and chronic impairment of renal function. (See <a href=\"#H7\" class=\"local\">'Clinical manifestations'</a> above.)</p><p>The likelihood of cisplatin-induced nephrotoxicity is increased with high peak plasma free platinum concentrations, previous therapy with <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, underlying chronic kidney disease (CKD), and concomitant use of other nephrotoxic agents. (See <a href=\"#H15\" class=\"local\">'Prevention'</a> above.)</p><p>A number of measures are potentially useful to prevent acute <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> nephrotoxicity and chronic renal impairment:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend intravenous isotonic saline to induce a diuresis before and after <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> administration (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H17\" class=\"local\">'Intravenous saline'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The optimal intravenous solution and regimen is unclear. We prepare a solution consisting of 1000 mL of isotonic saline plus 20 mEq of <a href=\"topic.htm?path=potassium-chloride-drug-information\" class=\"drug drug_general\">potassium chloride</a> and 2 grams of <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">magnesium sulfate</a>. Although there is no standard approach, we administer intravenously a minimum of 1000 mL of this solution over the two to three hours prior to, and 500 mL over the two hours following, the <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> administration to maintain a urine flow of at least 100 <span class=\"nowrap\">mL/hour</span> for two hours before and two hours after drug administration. Among patients in whom this regimen is contraindicated, therapeutic regimens that do <strong>not</strong> include cisplatin should be encouraged.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>There is no evidence that the use of chemopreventive agents, such as <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">amifostine</a>, is clinically useful in preventing nephrotoxicity in patients being treated with contemporary cisplatin-based regimens.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend <strong>not</strong> using <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> in most patients with underlying renal disease (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). Possible exceptions are situations in which cisplatin has a proven curative role, such as patients with testicular cancer. We recommend avoiding the coadministration of other potentially nephrotoxic agents, such as aminoglycosides, nonsteroidal anti-inflammatory agents, or iodinated contrast media (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). (See <a href=\"#H14\" class=\"local\">'Risk factors for acute kidney injury'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients in whom <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> is contraindicated or in whom there is an increased risk of nephrotoxicity, the substitution of <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> for cisplatin can be considered. (See <a href=\"#H8\" class=\"local\">'Renal impairment'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H2089504508\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Richard T Penson, MD, MRCP, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/1\" class=\"nounderline abstract_t\">Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/2\" class=\"nounderline abstract_t\">Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39:1362.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/3\" class=\"nounderline abstract_t\">Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39:1372.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/4\" class=\"nounderline abstract_t\">Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol 2018; 31:15.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/5\" class=\"nounderline abstract_t\">Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10:1663.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/6\" class=\"nounderline abstract_t\">Galea AM, Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta 2002; 1579:142.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/7\" class=\"nounderline abstract_t\">Litterst CL, Torres IJ, Guarino AM, et al. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP (II). J Clin Hematol Oncol 1977; 7:169.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/8\" class=\"nounderline abstract_t\">Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 1984; 25:753.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/9\" class=\"nounderline abstract_t\">Dobyan DC, Levi J, Jacobs C, et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213:551.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/10\" class=\"nounderline abstract_t\">Urakami Y, Okuda M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998; 287:800.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/11\" class=\"nounderline abstract_t\">Yokoo S, Yonezawa A, Masuda S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74:477.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/12\" class=\"nounderline abstract_t\">Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008; 14:3875.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/13\" class=\"nounderline abstract_t\">Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23:243.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/14\" class=\"nounderline abstract_t\">Hu S, Leblanc AF, Gibson AA, et al. Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. Clin Transl Sci 2017; 10:412.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/15\" class=\"nounderline abstract_t\">Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992; 7:1.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/16\" class=\"nounderline abstract_t\">Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985; 249:F490.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/17\" class=\"nounderline abstract_t\">Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110:835.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/18\" class=\"nounderline abstract_t\">Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289:F166.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/19\" class=\"nounderline abstract_t\">Kelly KJ, Meehan SM, Colvin RB, et al. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int 1999; 56:922.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/20\" class=\"nounderline abstract_t\">Li S, Gokden N, Okusa MD, et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:F469.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/21\" class=\"nounderline abstract_t\">Liu M, Chien CC, Burne-Taney M, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 2006; 17:765.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/22\" class=\"nounderline abstract_t\">Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285:F610.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/23\" class=\"nounderline abstract_t\">Faubel S, Ljubanovic D, Reznikov L, et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 2004; 66:2202.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/24\" class=\"nounderline abstract_t\">Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007; 72:37.</a></li><li class=\"breakAll\">Portilla D, Kaushal GP, Basnakian AG. Recent progress in the pathophysiology of acute renal failure. In: Principles of Molecular Medicine, 2nd ed., Runge MS, Patterson C (Eds), Humana Press, Totawa, NJ 2006. p.643.</li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/26\" class=\"nounderline abstract_t\">Xu EY, Perlina A, Vu H, et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem Res Toxicol 2008; 21:1548.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/27\" class=\"nounderline abstract_t\">Townsend DM, Deng M, Zhang L, et al. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14:1.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/28\" class=\"nounderline abstract_t\">Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31:971.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/29\" class=\"nounderline abstract_t\">Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001; 12:2683.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/30\" class=\"nounderline abstract_t\">Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994; 203:1175.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/31\" class=\"nounderline abstract_t\">Tanaka-Kagawa T, Kitahara J, Seko Y, et al. Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase. Biochem Pharmacol 1999; 57:545.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/32\" class=\"nounderline abstract_t\">Appenroth D, Fr&ouml;b S, Kersten L, et al. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 1997; 71:677.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/33\" class=\"nounderline abstract_t\">Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270:F700.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/34\" class=\"nounderline abstract_t\">McGinness JE, Proctor PH, Demopoulos HB, et al. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Physiol Chem Phys 1978; 10:267.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/35\" class=\"nounderline abstract_t\">Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 2002; 277:43377.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/36\" class=\"nounderline abstract_t\">Portilla D, Li S, Nagothu KK, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006; 69:2194.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/37\" class=\"nounderline abstract_t\">Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA. Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol 1999; 18:454.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/38\" class=\"nounderline abstract_t\">Li S, Wu P, Yarlagadda P, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004; 286:F572.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/39\" class=\"nounderline abstract_t\">Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68:2680.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/40\" class=\"nounderline abstract_t\">Negishi K, Noiri E, Sugaya T, et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int 2007; 72:348.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/41\" class=\"nounderline abstract_t\">Wittes RE, Brescia F, Young CW, et al. Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975; 32:202.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/42\" class=\"nounderline abstract_t\">Vasey PA. &quot;Dose dense&quot; chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15 Suppl 3:226.</a></li><li class=\"breakAll\">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.120.</li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/44\" class=\"nounderline abstract_t\">Kim SW, Lee JU, Nah MY, et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 2001; 12:875.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/45\" class=\"nounderline abstract_t\">Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167:1477.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/46\" class=\"nounderline abstract_t\">Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/47\" class=\"nounderline abstract_t\">Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90:929.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/48\" class=\"nounderline abstract_t\">Lam M, Adelstein DJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 1986; 8:164.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/49\" class=\"nounderline abstract_t\">Sutton RA, Walker VR, Halabe A, et al. Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 1991; 117:40.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/50\" class=\"nounderline abstract_t\">Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56:535.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/51\" class=\"nounderline abstract_t\">Goldstein RS, Mayor GH, Rosenbaum RW, et al. Glucose intolerance following cis-platinum treatment in rats. Toxicology 1982; 24:273.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/52\" class=\"nounderline abstract_t\">Goldstein RS, Mayor GH, Gingerich RL, et al. The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 1983; 69:432.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/53\" class=\"nounderline abstract_t\">Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54:208.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/54\" class=\"nounderline abstract_t\">Koch Nogueira PC, Hadj-A&iuml;ssa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998; 12:572.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/55\" class=\"nounderline abstract_t\">Hartmann JT, Fels LM, Knop S, et al. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000; 18:281.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/56\" class=\"nounderline abstract_t\">Hutchison FN, Perez EA, Gandara DR, et al. Renal salt wasting in patients treated with cisplatin. Ann Intern Med 1988; 108:21.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/57\" class=\"nounderline abstract_t\">Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. Am J Clin Oncol 2002; 25:344.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/58\" class=\"nounderline abstract_t\">Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/59\" class=\"nounderline abstract_t\">Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5:304.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/60\" class=\"nounderline abstract_t\">Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83:866.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/61\" class=\"nounderline abstract_t\">Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/62\" class=\"nounderline abstract_t\">Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/63\" class=\"nounderline abstract_t\">de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/64\" class=\"nounderline abstract_t\">de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19:3733.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/65\" class=\"nounderline abstract_t\">Motwani SS, McMahon GM, Humphreys BD, et al. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol 2018; 36:682.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/66\" class=\"nounderline abstract_t\">Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 1978; 23:461.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/67\" class=\"nounderline abstract_t\">Crona DJ, Faso A, Nishijima TF, et al. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist 2017; 22:609.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/68\" class=\"nounderline abstract_t\">Castiglione F, Dalla Mola A, Porcile G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 1999; 85:85.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/69\" class=\"nounderline abstract_t\">Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999; 26:72.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/70\" class=\"nounderline abstract_t\">Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20:2895.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/71\" class=\"nounderline abstract_t\">Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/72\" class=\"nounderline abstract_t\">Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986; 8:368.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/73\" class=\"nounderline abstract_t\">Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97:845.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/74\" class=\"nounderline abstract_t\">Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005; 312:424.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/75\" class=\"nounderline abstract_t\">Heidemann HT, M&uuml;ller S, Mertins L, et al. Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol 1989; 97:313.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/76\" class=\"nounderline abstract_t\">Benoehr P, Krueth P, Bokemeyer C, et al. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol 2005; 16:452.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/77\" class=\"nounderline abstract_t\">Heyman SN, Spokes K, Egorin MJ, Epstein FH. Glycine reduces early renal parenchymal uptake of cisplatin. Kidney Int 1993; 43:1226.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/78\" class=\"nounderline abstract_t\">Sengupta P, Basu S, Soni S, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012; 109:11294.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/79\" class=\"nounderline abstract_t\">Pabla N, Gibson AA, Buege M, et al. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A 2015; 112:5231.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/80\" class=\"nounderline abstract_t\">Bundy JT, Connito D, Mahoney MD, Pontier PJ. Treatment of idiopathic renal magnesium wasting with amiloride. Am J Nephrol 1995; 15:75.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/81\" class=\"nounderline abstract_t\">Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6:1728.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/82\" class=\"nounderline abstract_t\">Brock PR, Koliouskas DE, Barratt TM, et al. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991; 118:531.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/83\" class=\"nounderline abstract_t\">Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int 1989; 35:84.</a></li><li><a href=\"https://www.uptodate.com/contents/cisplatin-nephrotoxicity/abstract/84\" class=\"nounderline abstract_t\">Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249:F324.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7231 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H31\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Cellular toxicity</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Vasoconstriction</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Proinflammatory effects</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Effects on the proximal tubule</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Renal impairment</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Thrombotic microangiopathy</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Hypomagnesemia</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Fanconi-like syndrome</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Salt wasting</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Anemia</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">RISK FACTORS FOR ACUTE KIDNEY INJURY</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">PREVENTION</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Lower doses of cisplatin</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Intravenous saline</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Cisplatin analogs</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Amifostine</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Other chemopreventive agents</a><ul><li><a href=\"#H21\" id=\"outline-link-H21\">- Sodium thiosulfate</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">- N-acetylcysteine</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">- Theophylline</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">- Glycine</a></li><li><a href=\"#H554610594\" id=\"outline-link-H554610594\">- Polymeric cisplatin nanoparticles</a></li><li><a href=\"#H435708950\" id=\"outline-link-H435708950\">- Cell cycle inhibitors</a></li></ul></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">TREATMENT</a><ul><li><a href=\"#H26\" id=\"outline-link-H26\">General approach to renal dysfunction or failure</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">Discontinuation of cisplatin</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">Hypomagnesemia</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">Thrombotic microangiopathy</a></li></ul></li><li><a href=\"#H30\" id=\"outline-link-H30\">PROGNOSIS</a></li><li><a href=\"#H354165833\" id=\"outline-link-H354165833\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H2089504508\" id=\"outline-link-H2089504508\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-ttp-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Acquired TTP: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents\" class=\"medical medical_review\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">Drug-induced thrombotic microangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-treatment-of-hypomagnesemia\" class=\"medical medical_review\">Evaluation and treatment of hypomagnesemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extensive-stage-small-cell-lung-cancer-initial-management\" class=\"medical medical_review\">Extensive stage small cell lung cancer: Initial management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ovarian-fallopian-tubal-and-peritoneal-cancer\" class=\"medical medical_review\">First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-risk-stratified-treatment-for-advanced-testicular-germ-cell-tumors\" class=\"medical medical_review\">Initial risk-stratified treatment for advanced testicular germ cell tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-and-pathophysiology-of-renal-tubular-acidosis-and-the-effect-on-potassium-balance\" class=\"medical medical_review\">Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-acute-kidney-injury-in-adults\" class=\"medical medical_review\">Overview of the management of acute kidney injury in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-acquired-ttp-and-other-primary-thrombotic-microangiopathies-tmas\" class=\"medical medical_review\">Pathophysiology of acquired TTP and other primary thrombotic microangiopathies (TMAs)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-magnesium-balance\" class=\"medical medical_review\">Regulation of magnesium balance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-kidney-injury-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Acute kidney injury in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-the-initial-management-of-advanced-non-small-cell-lung-cancer-without-a-driver-mutation\" class=\"medical medical_review\">Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation</a></li></ul></div></div>","javascript":null}